The financials
Arcutis Biotherapeutics, Inc. by the numbers
Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $130M in Q2 2026 (quarter ended June 30, 2026), up 59% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $15M (12% of revenue). For the full year FY2025, revenue was $376M (+91% year on year) and net income −$16M. Its largest product in 2026-Q1 was ZORYVE Foam at $50M, 47% of the disclosed total, just ahead of ZORYVE Cream0.3 at 31%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $130M | $82M | +59% |
| Gross profit | $119M | $74M | +61% |
| Operating income | $16M | −$15M | to a profit |
| Net income | $15M | −$16M | to a profit |
| Diluted EPS | $0.11 | −$0.13 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| ZORYVE Foam | $50M | 47% |
| ZORYVE Cream0.3 | $33M | 31% |
| ZORYVE Cream0.15 | $22M | 21% |
| ZORYVE Cream0.05 | $1.4M | 1.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $105.4M (+6.2%)
ZORYVE Cream0.15 grew +113% year on yearZORYVE Cream0.3 +40% year on year
Segment Latestquarter on quarteryear on year
- ZORYVE Foam$49.6M$49.6MQoQ -0.31%year on year +64%-0.31%+64%
- ZORYVE Cream0.3$32.7M$32.7MQoQ +7.1%year on year +40%+7.1%+40%
- ZORYVE Cream0.15$21.7M$21.7MQoQ +15%year on year +113%+15%+113%
- ZORYVE Cream0.05$1.4M$1.4MQoQ -year on year ---
- ZORYVE Cream--QoQ -year on year ---